379 related articles for article (PubMed ID: 11346877)
21. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.
Olieman AF; Liénard D; Eggermont AM; Kroon BB; Lejeune FJ; Hoekstra HJ; Koops HS
Arch Surg; 1999 Mar; 134(3):303-7. PubMed ID: 10088573
[TBL] [Abstract][Full Text] [Related]
22. Increased shedding of soluble TNF-receptor 1 during hyperthermic TNF-α-based isolated limb perfusion.
Grabellus F; Podleska LE; Bjerlestam S; Sheu SY; Lendemans S; Schmid KW; Taeger G
Int J Hyperthermia; 2011; 27(1):33-41. PubMed ID: 21073296
[TBL] [Abstract][Full Text] [Related]
23. Hyperthermic isolated limb perfusion. The switch from Steinmann pins to Omni-tract assisted isolation.
Stamatiou D; Ioannou CV; Kontopodis N; Michelakis D; Perisinakis K; Lasithiotakis K; Zoras O
J Surg Res; 2017 Jun; 213():147-157. PubMed ID: 28601307
[TBL] [Abstract][Full Text] [Related]
24. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor.
Olieman AF; van Ginkel RJ; Hoekstra HJ; Mooyaart EL; Molenaar WM; Koops HS
Ann Surg Oncol; 1997 Jan; 4(1):64-9. PubMed ID: 8985519
[TBL] [Abstract][Full Text] [Related]
25. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer.
van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ
J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833
[TBL] [Abstract][Full Text] [Related]
26. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.
Rossi CR; Mocellin S; Pilati P; Foletto M; Campana L; Quintieri L; De Salvo GL; Lise M
Ann Surg Oncol; 2005 May; 12(5):398-405. PubMed ID: 15915374
[TBL] [Abstract][Full Text] [Related]
27. Multidrug resistance proteins in primary and metastatic soft-tissue sarcomas: down-regulation of P-glycoprotein during metastatic progression.
Komdeur R; Molenaar WM; Zwart N; Hoekstra HJ; van den Berg E; van der Graaf WT
Anticancer Res; 2004; 24(1):291-5. PubMed ID: 15015610
[TBL] [Abstract][Full Text] [Related]
28. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
[TBL] [Abstract][Full Text] [Related]
29. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
30. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
[TBL] [Abstract][Full Text] [Related]
31. Hyperthermic isolated limb perfusion for extremity sarcomas.
Kim CJ; Puleo C; Letson GD; Reintgen D
Cancer Control; 2001; 8(3):269-73. PubMed ID: 11378653
[TBL] [Abstract][Full Text] [Related]
32. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
Issakov J; Merimsky O; Gutman M; Kollender Y; Lev-Chelouche D; Abu-Abid S; Lifschitz-Mercer B; Inbar M; Klausner JM; Meller I
Ann Surg Oncol; 2000 Mar; 7(2):155-9. PubMed ID: 10761796
[TBL] [Abstract][Full Text] [Related]
33. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications.
Diestra JE; Condom E; Del Muro XG; Scheffer GL; Pérez J; Zurita AJ; Muñoz-Seguí J; Vigués F; Scheper RJ; Capellá G; Germà-Lluch JR; Izquierdo MA
J Urol; 2003 Oct; 170(4 Pt 1):1383-7. PubMed ID: 14501774
[TBL] [Abstract][Full Text] [Related]
34. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.
Eggermont AM; ten Hagen TL
Curr Oncol Rep; 2001 Jul; 3(4):359-67. PubMed ID: 11389822
[TBL] [Abstract][Full Text] [Related]
35. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.
van Ginkel RJ; Hoekstra HJ; Pruim J; Nieweg OE; Molenaar WM; Paans AM; Willemsen AT; Vaalburg W; Koops HS
J Nucl Med; 1996 Jun; 37(6):984-90. PubMed ID: 8683328
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences.
Grabellus F; Kraft C; Sheu SY; Ebeling P; Bauer S; Lendemans S; Schmid KW; Taeger G
Ann Surg Oncol; 2009 Mar; 16(3):676-86. PubMed ID: 19130134
[TBL] [Abstract][Full Text] [Related]
37. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
[TBL] [Abstract][Full Text] [Related]
38. Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma.
Andreou D; Werner M; Pink D; Traub F; Schuler MK; Gosheger G; Jobke B; Reichardt P; Tunn PU
Int J Hyperthermia; 2016; 32(2):159-64. PubMed ID: 26670477
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.
Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S
Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998
[TBL] [Abstract][Full Text] [Related]
40. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
